Ultra-Sensitive Proteomic Quantitation of Circulating TB Biomarker Candidates by Complete Proteome SRM Assays

Robert Moritz and colleagues at the Institute for Systems Biology and Seattle Biomed in the U.S. will use ultra-sensitive targeted assay technology to identify, quantify, and validate a library of biomarker candidates specific to both active and latent TB infection. Moritz and his team hope to discover highly specific proteins that could help determine disease status at the point of care and inform appropriate treatment.